.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,635,278

« Back to Dashboard

Claims for Patent: 6,635,278

Title: Pharmaceutical formulations
Abstract:The invention provides compositions comprising the nucleotide analog 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and an alkaline excipient with or without L-carnitine-L-tartrate. The compositions are more stable those previously described. The invention also provides methods to make the compositions and their intermediates.
Inventor(s): Dahl; Terrence C. (Sunnyvale, CA), Yuan; Lung-Chi J. (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:09/211,613
Patent Claims: 1. A composition consisting essentially of 9-[2-[bis(pivaloyloxy)methyl]phosphonomethoxyl]ethyl]adenine and an alkaline excipient, having a pKa of the conjugated acid of at least about 4.0 and a Ksp of about 1.times.10.sup.-3 to about 1.times.10.sup.-15.

2. The composition of claim 1 wherein the loss on drying (LOD) at 75.degree. C. is no more than 5%.

3. The composition of claim 2 wherein the alkaline excipient is an alkaline carbonate or an alkaline hydroxide.

4. The composition of claim 3 wherein the alkaline carbonate is calcium carbonate, magnesium carbonate, zinc carbonate, manganese carbonate, aluminum carbonate, ferrous carbonate or cobalt carbonate.

5. The composition of claim 2 wherein the alkaline hydroxide is magnesium hydroxide, calcium hydroxide, aluminum hydroxide or iron hydroxide.

6. The composition of claim 2 wherein the LOD 75.degree. C. is no more than about 2%.

7. The composition of claim 2 wherein the LOD 75.degree. C. is no more than about 1.5%.

8. The composition of claim 1 wherein the alkaline excipient comprises about 1-20% of the composition.

9. The composition of claim 8 wherein the alkaline excipient is an alkaline carbonate or an alkaline hydroxide.

10. The composition of claim 9 wherein the alkaline carbonate is calcium carbonate, magnesium carbonate, zinc carbonate, manganese carbonate, aluminum carbonate, ferrous carbonate or cobalt carbonate.

11. The composition of claim 9 wherein the alkaline hydroxide is magnesium hydroxide, aluminum hydroxide or iron hydroxide.

12. The composition of claim 9 wherein the alkaline excipient comprises about 2-6%.

13. The composition of claim 8 wherein the composition is a unit dose.

14. The unit dose of claim 13 comprising a tablet containing about 1.0-300 mg of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine.

15. The tablet or capsule of claim 13 wherein the tablet or capsule comprises about 5-30% w/w of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine.

16. The tablet or capsule of claim 15 wherein the tablet or capsule comprises about 2-6% w/w of an alkaline excipient.

17. The tablet of claim 16 wherein the tablet comprises about 2-6% w/w of an alkaline excipient selected from the group consisting of calcium carbonate, magnesium carbonate, zinc carbonate, manganese carbonate, aluminum carbonate, ferrous carbonate and cobalt carbonate.

18. The tablet of claim 17 wherein the tablet comprises about 35-80% w/w of lactose monohydrate, anhydrous lactose, or microcrystalline cellulose.

19. The tablet or capsule of claim 17, wherein the tablet or capsule comprises about 20-50% w/w L-carnitine-L-tartrate, L-carnitine-L-fumarate or microencapsulated L-carnitine, about 4-20% w/w 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and about 1-6% w/w alkaline excipient.

20. The composition comprising about 10 mg of 9-[2-[[bis[(pivaloyloxy)-methyl]phosphono]methoxyl]ethyl]adenine, about 1-5 mg magnesium carbonate or calcium carbonate, about 4-8 mg croscarmellose sodium, about 5 mg pregelatinized starch, about 40-65 mg lactose, about 15-35 mg microcrystalline cellulose, about 0-6 mg talc, and about 0.5-2 mg magnesium stearate.

21. The composition comprising about 30 mg of 9-[2-[[bis[(pivaloyloxy)-methyl]phosphono]methoxyl]ethyl]adenine, about 410 mg magnesium carbonate, 61.5-75.25 mg lactose monohydrate or anhydrous lactose, about 22.5 mg of microcrystalline cellulose, about 7.5 mg of pregelatinized starch, about 9 mg of croscarmellose sodium, about 0-9 mg talc and about 0.75-1.5 mg magnesium stearate.

22. The composition comprising about 60 mg of 9-[2-[[bis[(pivaloyloxy)-methyl]phosphono]methoxyl]ethyl]adenine, about 12 mg magnesium carbonate, about 73 mg lactose monohydrate or anhydrous lactose, about 30 mg of microcrystalline cellulose, about 10 mg of pregelatinied starch, about 12 mg of croscanellose sodium, about 1 mg silicon dioxide and about 2 mg magnesium stearate.

23. The composition comprising about 120 mg of 9-[2-[[bis[(pivaloyloxy)-methyl]phosphono]methoxyl]ethyl]adenine, about 12-24 mg magnesium carbonate, about 124-162 mg lactose monohydrate or anhydrous lactose, about 60 mg microcrystalline cellulose, about 20 mg pregelatinized starch, about 24 mg of croscarmellose sodium, about 0-24 mg talc and about 2-4 mg magnesium stearate.

24. The composition comprising about 4-8% w/w of 9-[2-[[bis[(pivaloyloxy)-methyl]phosphono]methoxyl]ethyl]adenine, about 16-% w/w magnesium carbonate, about 24-51% w/w L-carnitine-L-tartrate, about 20-36% w/w niicrocrystalline cellulose, about 5% w/w pregelatinized starch, about 4% w/w croscarmellose sodium and (1) about 1% w/w sodium stearyl fumarate or (2) about 2% w/w talc and about 1% w/w type I hydrogenated vegetable oil.

25. The composition of claim 1 in the form of dried granules having a LOD of no more than about 2.0%.

26. The composition of claim 1 which contains an additional excipient selected from the group consisting of a binder, disintegrant, diluent, lubricant, glidant, coloring agent and flavoring agent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc